Table 2. Additional analysis of pleural fibrosis and irritation on extra histology samples.
| Histological response | 5 days | 14 days | 42 days |
|---|---|---|---|
| Pleural thickening | |||
| Lung without lesion | 1/4 (75.0) | 4/4 (100.0) | 4/4 (100.0) |
| Parietal pleura† | 0/9 (0.0) | 4/12 (33.3) | 1/12 (8.3) |
| Across NHS-POx | N/A | 2/4 (50.0) | 2/4 (50.0) |
| Across fibrin patch | N/A | 3/4 (75.0) | 2/3 (66.7) |
| Across control lesion | N/A | 2/4 (50.0) | 3/4 (75.0) |
| Total | 1/13 (7.7) | 15/28 (53.6) | 12/27 (44.4) |
| Pleural irritation‡ | |||
| Lung without lesion | 2/4 (50.0) | 3/4 (75.0) | 0/4 (0.0) |
| Parietal pleura† | 3/9 (33.3) | 6/12 (50.0) | 0/12 (0.0) |
| Across NHS-POx | N/A | 4/4 (100.0) | 0/4 (0.0) |
| Across fibrin patch | N/A | 4/4 (100.0) | 1/3 (33.3) |
| Across control lesion | N/A | 3/4 (75.0) | 2/4 (50.0) |
| Total | 5/13 (38.5) | 20/28 (71.4) | 3/27 (11.1) |
Data are presented as number/total (%). †, apical, lateral, costodiaphragmatic recess samples. ‡, based on immune cell infiltration, fibrinoid pleuritis, reactive mesothelial cells, neovascularization. N/A, not available; NHS-POx, N-hydroxysuccinimide ester functionalized poly(2)oxazolines.